Physician profile
Mohammad Umar Farooq
NPI 1750622924
$1,041.77
in general payments reported to CMS, 2019-2025
14 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2023: $226 · 2024: $498 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.80 |
| Education | $174.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $261.25 | 2023-2025 | Lifevest |
| Pfizer INC. | $191.08 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.96 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $105.81 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $78.86 | 2023-2024 | |
| Abbott Laboratories | $43.67 | 2024-2025 | Cardiomems, Gallant |
| Sunovion Pharmaceuticals INC. | $35.18 | 2019 | |
| Genzyme Corporation | $35.00 | 2024 | |
| Boston Scientific Corporation | $34.78 | 2025 | Accolade Sr |
| Abiomed | $25.30 | 2023 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $24.75 | 2024 | Arcalyst |
| Biogen, INC. | $24.43 | 2024 | Skyclarys |
| Terumo Medical Corporation | $20.83 | 2024 | Angio-Seal |
| Medtronic, INC. | $17.87 | 2025 | Azure Xt Dr Mri Surescan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.